Clinical and Life Sciences · 3 October 2026 to 3 October 2026 · 1 headlines · MedPage Today
Non-Covalent BTK Drug Wins Broad Approval in Most Common Leukemia
A non-covalent BTK inhibitor drug has received broad approval for treating the most common form of leukemia.
As it ran
3 October 2026
More from US healthcare
- Restoring public trust in science doesn’t have a simple solution. That’s OK 3 October 2026
- CommonSpirit targets $1B in cost reductions 3 October 2026
- Lilly's weekly insulin and direct-to-consumer strategy 2 October 2026
- Advances in myasthenia gravis treatment 2 October 2026
- Retatrutide weight loss trial results 2 October 2026
- 3 medical device recalls to know 2 October 2026
- An Ebola treatment center was burned down as the death toll in Congo passes 4,000 2 October 2026
- Cancer GoFundMe Shut Down; 'Dialed Down' Drug Price Plan; Binge Drinking and Cancer 2 October 2026